698 related articles for article (PubMed ID: 18055253)
1. Detection of human influenza A (H1N1) and B strains with reduced sensitivity to neuraminidase inhibitors.
Escuret V; Frobert E; Bouscambert-Duchamp M; Sabatier M; Grog I; Valette M; Lina B; Morfin F; Ferraris O
J Clin Virol; 2008 Jan; 41(1):25-8. PubMed ID: 18055253
[TBL] [Abstract][Full Text] [Related]
2. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice.
Ferraris O; Kessler N; Lina B
Antiviral Res; 2005 Oct; 68(1):43-8. PubMed ID: 16125799
[TBL] [Abstract][Full Text] [Related]
3. Surveillance and oseltamivir resistance of human influenza a virus in Turkey during the 2007-2008 season.
Ciblak MA; Hasoksuz M; Escuret V; Valette M; Gul F; Yilmaz H; Turan N; Bozkaya E; Badur S
J Med Virol; 2009 Sep; 81(9):1645-51. PubMed ID: 19626608
[TBL] [Abstract][Full Text] [Related]
4. Neuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009-2010 and 2010-2011 influenza seasons in Japan.
Dapat C; Kondo H; Dapat IC; Baranovich T; Suzuki Y; Shobugawa Y; Saito K; Saito R; Suzuki H
Antiviral Res; 2013 Sep; 99(3):261-9. PubMed ID: 23791870
[TBL] [Abstract][Full Text] [Related]
5. Genotypic and phenotypic resistance of pandemic A/H1N1 influenza viruses circulating in Germany.
Duwe SC; Wedde M; Birkner P; Schweiger B
Antiviral Res; 2011 Jan; 89(1):115-8. PubMed ID: 21070812
[TBL] [Abstract][Full Text] [Related]
6. Genetic microheterogeneity of emerging H275Y influenza virus A (H1N1) in Toronto, Ontario, Canada from the 2007-2008 respiratory season.
Eshaghi A; Bolotin S; Burton L; Low DE; Mazzulli T; Drews SJ
J Clin Virol; 2009 Jun; 45(2):142-5. PubMed ID: 19451021
[TBL] [Abstract][Full Text] [Related]
7. Host cell selection of influenza neuraminidase variants: implications for drug resistance monitoring in A(H1N1) viruses.
Okomo-Adhiambo M; Nguyen HT; Sleeman K; Sheu TG; Deyde VM; Garten RJ; Xu X; Shaw MW; Klimov AI; Gubareva LV
Antiviral Res; 2010 Feb; 85(2):381-8. PubMed ID: 19917319
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of antiviral-resistant influenza viruses in the Netherlands, 2005-2008.
Jonges M; van der Lubben IM; Dijkstra F; Verhoef L; Koopmans M; Meijer A
Antiviral Res; 2009 Sep; 83(3):290-7. PubMed ID: 19591877
[TBL] [Abstract][Full Text] [Related]
9. Influenza A(H1N1)pdm09 resistance and cross-decreased susceptibility to oseltamivir and zanamivir antiviral drugs.
Correia V; Santos LA; Gíria M; Almeida-Santos MM; Rebelo-de-Andrade H
J Med Virol; 2015 Jan; 87(1):45-56. PubMed ID: 25042157
[TBL] [Abstract][Full Text] [Related]
10. Detection of the rapid emergence of the H275Y mutation associated with oseltamivir resistance in severe pandemic influenza virus A/H1N1 09 infections.
Wang B; Dwyer DE; Blyth CC; Soedjono M; Shi H; Kesson A; Ratnamohan M; McPhie K; Cunningham AL; Saksena NK
Antiviral Res; 2010 Jul; 87(1):16-21. PubMed ID: 20385168
[TBL] [Abstract][Full Text] [Related]
11. Different neuraminidase inhibitor susceptibilities of human H1N1, H1N2, and H3N2 influenza A viruses isolated in Germany from 2001 to 2005/2006.
Bauer K; Richter M; Wutzler P; Schmidtke M
Antiviral Res; 2009 Apr; 82(1):34-41. PubMed ID: 19428593
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the antiviral drug susceptibility of influenza viruses in Italy from 2004/05 to 2009/10 epidemics and from the recent 2009 pandemic.
Puzelli S; Facchini M; Di Martino A; Fabiani C; Lackenby A; Zambon M; Donatelli I
Antiviral Res; 2011 Jun; 90(3):205-12. PubMed ID: 21514326
[TBL] [Abstract][Full Text] [Related]
13. Analysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United States.
Nguyen HT; Trujillo AA; Sheu TG; Levine M; Mishin VP; Shaw M; Ades EW; Klimov AI; Fry AM; Gubareva LV
Antiviral Res; 2012 Mar; 93(3):381-6. PubMed ID: 22330888
[TBL] [Abstract][Full Text] [Related]
14. Oseltamivir-resistant pandemic influenza a (H1N1) 2009 viruses in Spain.
Ledesma J; Vicente D; Pozo F; Cilla G; Castro SP; Fernández JS; Ruiz MP; Navarro JM; Galán JC; Fernández M; Reina J; Larrauri A; Cuevas MT; Casas I; Breña PP;
J Clin Virol; 2011 Jul; 51(3):205-8. PubMed ID: 21592854
[TBL] [Abstract][Full Text] [Related]
15. Antiviral drug susceptibilities of seasonal human influenza viruses in Lebanon, 2008-09 season.
Zaraket H; Saito R; Wakim R; Tabet C; Medlej F; Reda M; Baranovich T; Suzuki Y; Dapat C; Caperig-Dapat I; Dbaibo GS; Suzuki H
J Med Virol; 2010 Jul; 82(7):1224-8. PubMed ID: 20513088
[TBL] [Abstract][Full Text] [Related]
16. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007.
Tashiro M; McKimm-Breschkin JL; Saito T; Klimov A; Macken C; Zambon M; Hayden FG;
Antivir Ther; 2009; 14(6):751-61. PubMed ID: 19812437
[TBL] [Abstract][Full Text] [Related]
17. Emergence and spread of oseltamivir-resistant A(H1N1) influenza viruses in Oceania, South East Asia and South Africa.
Hurt AC; Ernest J; Deng YM; Iannello P; Besselaar TG; Birch C; Buchy P; Chittaganpitch M; Chiu SC; Dwyer D; Guigon A; Harrower B; Kei IP; Kok T; Lin C; McPhie K; Mohd A; Olveda R; Panayotou T; Rawlinson W; Scott L; Smith D; D'Souza H; Komadina N; Shaw R; Kelso A; Barr IG
Antiviral Res; 2009 Jul; 83(1):90-3. PubMed ID: 19501261
[TBL] [Abstract][Full Text] [Related]
18. Allele-specific conventional reverse-transcription polymerase chain reaction as a screening assay for discriminating influenza a H1N1 (H275Y) oseltamivir-resistant and wild-type viruses.
Ngai KL; Lam WY; Lee N; Leung TF; Hui DS; Chan PK
J Med Virol; 2010 Aug; 82(8):1295-8. PubMed ID: 20572070
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir.
Hurt AC; Barr IG; Hartel G; Hampson AW
Antiviral Res; 2004 Apr; 62(1):37-45. PubMed ID: 15026200
[TBL] [Abstract][Full Text] [Related]
20. A two-year survey of the oseltamivir-resistant influenza A(H1N1) virus in Yamagata, Japan and the clinical effectiveness of oseltamivir and zanamivir.
Matsuzaki Y; Mizuta K; Aoki Y; Suto A; Abiko C; Sanjoh K; Sugawara K; Takashita E; Itagaki T; Katsushima Y; Ujike M; Obuchi M; Odagiri T; Tashiro M
Virol J; 2010 Mar; 7():53. PubMed ID: 20202225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
